Medicare

New & Noteworthy
Examining the Potential Impact of Medicare’s New WISeR Model

A federal initiative to establish new prior authorization requirements in traditional Medicare, called the Wasteful and Inappropriate Service Reduction (WISeR) model, is likely to have only modest impact in its first year.

State Profiles for Dual-Eligible Individuals

This data collection draws on Medicare and Medicaid administrative data to present national and state-level information on people who are covered by both Medicare and Medicaid, referred to as dual-eligible individuals (also known as dually-enrolled beneficiaries).

Data Visualization

The Facts About Medicare Spending

This interactive provides the facts on Medicare spending. Medicare, which serves 67 million people and accounts for 12 percent of the federal budget and 21 percent of national health spending, is often the focus of discussions about health expenditures, health care affordability and the sustainability of federal health programs.

Explore data on enrollment growth, Medicare spending trends overall and per person, growth in Medicare spending relative to private insurance, spending on benefits and Medicare Advantage, Part A trust fund solvency challenges, and growth in out-of-pocket spending by beneficiaries.

Related: FAQs on Medicare Financing and Trust Fund Solvency

Read More

Subscribe to KFF Emails

Choose which emails are best for you.
Sign up here

Filter

221 - 230 of 1,590 Results

  • What Are the Primary Medicaid Eligibility Pathways for Dual-Eligible Individuals?

    Issue Brief

    This brief examines current Medicaid eligibility policies and enrollment patterns using data from KFF’s 2024 50-state survey of states’ eligibility and enrollment policies for seniors and people with disabilities, and 2021 Medicare and Medicaid claims data from the Centers for Medicare and Medicaid Services (CMS).

  • What to Know About Medicare Coverage of Telehealth

    Issue Brief

    Many pandemic-era flexibilities around Medicare coverage of telehealth are due to expire in December 2024. There is bipartisan support for proposed legislation to extend these provisions for another two years, and Congress is weighing the potential benefits, risks, and costs of permanently expanding Medicare coverage of telehealth services. These FAQs provide answers to key questions about the current scope of Medicare telehealth coverage, including both temporary and permanent changes adopted through legislation and regulation, and policy considerations that lie ahead.

  • Misinformation About Immigrants in the 2024 Presidential Election

    Poll Finding

    With the 2024 election season underway, a large majority of the public reports hearing false claims about immigrants from candidates or elected officials, and many immigrants say Donald Trump's rhetoric in particular is negatively affecting how they are treated. This poll finding also gauges understanding about U.S. immigrants' eligibility for government benefits programs.

  • Key Facts About Medicare Part D Enrollment, Premiums, and Cost Sharing in 2024

    Issue Brief

    This brief analyzes 2024 Medicare Part D enrollment, premiums, and cost sharing. The analysis highlights the continued growth in Medicare Advantage enrollment in the Part D marketplace and substantially higher average monthly premiums for stand-alone Part D drug plan coverage. Changes to the Part D benefit included in the Inflation Reduction Act are helping to lower out-of-pocket costs for patients but could also contribute to higher-priced Part D coverage.

  • KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs

    Feature

    KFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro. This includes 6% who say they are currently taking one of the drugs.

  • Millions of People with Medicare Will Benefit from the New Out-of-Pocket Drug Spending Cap Over Time

    Issue Brief

    In 2025, Medicare beneficiaries will pay no more than $2,000 out of pocket for prescription drugs covered under Part D, Medicare’s outpatient drug benefit, due to a provision in the Inflation Reduction Act of 2022. This analysis examines how many Medicare Part D enrollees spent $2,000 or more out of pocket in 2021 and over multiple years, both nationally and at the state level, to show how many people over time could benefit from the new Part D spending cap.

  • 10 Things to Know About Medicare Advantage Dual-Eligible Special Needs Plans (D-SNPs)

    Issue Brief

    In 2023, 5.2 million dual-eligible individuals were enrolled in a Medicare Advantage plan designed specifically for dual-eligible individuals, known as Dual-Eligible Special Needs Plans (D-SNPs). This brief highlights 10 things to know about D-SNPs, including national and state enrollment trends, plan availability, insurer participation, benefits, and prior authorization rates and denials